HGH.AX(HGH.AX)
HGH.AX
No analyst ratings available
No analyst price targets available for HGH.AX
Analyst coverage may not be available for this symbol
No recent analyst actions
| Metric | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|
| Revenue Avg | $342M | $399M | $386M | $432M |
| Low | $342M | $399M | $386M | $432M |
| High | $342M | $399M | $386M | $432M |
| EBITDA Avg | $173M | $202M | $196M | $219M |
| Low | $173M | $202M | $196M | $219M |
| High | $173M | $202M | $196M | $219M |
| EBIT Avg | $151M | $176M | $171M | $191M |
| Low | $151M | $176M | $171M | $191M |
| High | $151M | $176M | $171M | $191M |
| Net Income Avg | $84M | $101M | $105M | $122M |
| Low | $82M | $96M | $105M | $122M |
| High | $85M | $107M | $105M | $122M |
| EPS Avg | $0.09 | $0.11 | $0.11 | $0.13 |
| Low | $0.09 | $0.10 | $0.11 | $0.13 |
| High | $0.09 | $0.11 | $0.11 | $0.13 |
| Analysts (Rev / EPS) | 1 / 2 | 1 / 2 | 1 / 1 | 1 / 1 |
| Metric | Q4 2026 |
|---|---|
| Revenue Avg | $141M |
| Low | $141M |
| High | $141M |
| EBITDA Avg | $71M |
| Low | $71M |
| High | $71M |
| EBIT Avg | $62M |
| Low | $62M |
| High | $62M |
| Net Income Avg | $49M |
| Low | $49M |
| High | $49M |
| EPS Avg | $0.06 |
| Low | $0.06 |
| High | $0.06 |
| Analysts (Rev / EPS) | 1 / 1 |